Chongqing Genrix Biopharmaceutical Co Ltd
Company Profile
Business description
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Contact
No. 699, Maliu Avenue
Area A, Building 2
International Bio City
Banan
Chongqing401338
CHNT: +86 2361758666
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
743
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.30 | 125.30 | -1.44% |
| CAC 40 | 7,731.74 | 5.54 | 0.07% |
| DAX 40 | 22,570.17 | 83.69 | -0.37% |
| Dow JONES (US) | 46,286.80 | 78.33 | 0.17% |
| FTSE 100 | 9,931.25 | 37.10 | 0.37% |
| HKSE | 25,063.71 | 681.24 | 2.79% |
| NASDAQ | 21,822.89 | 123.87 | -0.56% |
| Nikkei 225 | 52,252.28 | 736.79 | 1.43% |
| NZX 50 Index | 12,701.75 | 288.24 | -2.22% |
| S&P 500 | 6,575.65 | 5.35 | -0.08% |
| S&P/ASX 200 | 8,379.40 | 125.20 | -1.47% |
| SSE Composite Index | 3,881.28 | 68.00 | 1.78% |